cyrilzakka/clinical-trials huggingface dataset:
Sensory Study: Taste and Tongue Biology

Researchers will investigate the correlation between a) self-reported dietary intake of foods and beverages, b) intensity of sucrose stimuli, and c) liking rating of sweet stimuli, with the relative expression of the taste receptor genes from human fungiform papillae (TAS1R2 and TAS1R3).

\* This research will provide new information on how sweet taste perception is regulated.

* The hypothesis: Greater dietary consumption of sugar and sweet foods is associated with reduced expression of the sweet taste receptors.
* The results of this study could help to identify pathways to help modify sweet taste perception by uncovering this mechanism.

Participants will sample solutions prepared with sweet ingredients, provide salivary DNA, and collect fungiform papillae. This will allow researchers and investigators to compare the relationship between the sweetness of stimuli, genetic differences in sweet taste receptors, and expression levels of sweet taste receptor genes.


Eligibility Criteria:
Inclusion Criteria:

1. between 18 and 45 years old,
2. have no tongue or cheek piercings,
3. not a user of tobacco products or electronic cigarettes (within the last year),
4. no known defects in taste or smell,
5. not pregnant or breastfeeding,
6. no history of chronic pain in the mouth,
7. not taking any prescription pain medication,
8. not taking any blood thinners,
9. no history of cancer or cancer treatment,
10. not diabetic or restricting intake of sugars for medical reasons, under the direction of a physician or healthcare provider
11. willing to undergo the Fungiform Papillae biopsy procedure
12. willing to provide salivary DNA
13. Not currently experiencing any COVID-19 symptoms
14. Not recently diagnosed (in the last 30 days) with COVID-19
15. No history of high blood pressure

Exclusion Criteria:

-
Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer

What is the best dosage of Nab-Paclitaxel for chinese? This study would divide patients into two dosage groups: 1) 125mg/m2, 30 minutes intravenous injection, d1, 8, 21 days for a cycle(clinical use); 2) 125mg/m2 d1, 8, 15, 30 minutes intravenous injection, 28 days for a cycle(guideline recommand). Treatment to disease progression. The efficacy (CR, PR, SD, PD) is evaluated every 2-4 cycles.If the patient withdraws from the trial because he cannot tolerate the toxicity caused by one of the drugs, such as neurotoxicity or bone marrow toxicity, it is recommended to switch to other drugs and follow up to PFS and OS.Each group was planned to include 30 patients.


Eligibility Criteria:
Inclusion criteria

* Female, aged≥ 18 years old;
* Histopathologically confirmed HER-2 negative (definition: immunohistochemical IHC 0, or 1+, or in situ hybridization ISH, defined as the ratio of HER2 gene copy number to CEP17 signal number less than 2.0, or for single probe detection, HER2 gene copy number less than 6) in patients with recurrent or metastatic breast cancer;
* Up to two previous lines of chemotherapy were permitted for recurrent and metastatic diseases. And for endocrine therapy, the number of treatment lines can be omitted;
* With measurable lesions;
* The physical condition score of the Eastern American Cancer Collaboration Group (ECOG) was less than 1;
* Expected survival period\>3 months;

Exclusion Criteria

* New York Heart Association NYHA scores identify patients with congestive heart failure at grade II or above;Uncontrolled brain metastasis;
* Patients with severe systemic infection;Patients with peripheral nerve injury of degree II or above, or known drug allergy or intolerance within 4 weeks before admission;
* Important organ disorders or diseases: liver and kidney dysfunction, history of myocardial infarction, unstable heart disease, chronic active hepatitis,etc;There is a history of other malignant tumors within 5 years (except cured cervical cancer or skin basal cell carcinoma);
* Patients who had received other antineoplastic treatments or other experimental drugs within one month before treatment;
* Patients who also participated in other clinical trials;
* Researchers believe that patients are not suitable for any medical condition to enter the study.
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell lung cancer

1. Phase II/III study,
2. Randomized, multicenter, open-label study,
3. Evaluated the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy compared with chemotherapy in patients with stage IIIb-IV squamous non-small-cell lung cancer

Eligibility Criteria:
Inclusion Criteria:

* Sex: male or female
* Age: from 18 to 80 years
* Histology: squamous non-small-cell lung cancer
* Clinical stage: from stage IIIb to stage IV
* Therapy: not received chemotherapy, radiotherapy, or immunotherapy before entry into this study
* Karnofsky performance status: more than 50%
* Expected survival: more than 2 months
* Laboratory tests results 7 days before the start of treatment:

White blood cells: more than 3.0 × 109/L Platelets: more than 100 × 109/L Neutrophils: more than 1.5 × 109/L Hemoglobin: more than 80g/L Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN) Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN Serum bilirubin: less than 1.25 × ULN Serum creatinine: less than 1.25 × ULN

* pregnancy test: the test of women of child-bearing period must be negative 7 days before the start of treatment
* Contraception: male and female subjects of child-bearing period must adopt a reliable method of contraception before entry into this study until 30 days after stopping this study
* Informed consent: subject must have the ability to understand and voluntarily sign a written informed consent

Exclusion Criteria:

* History of neoplasms: other neoplasms
* Medical history: mental disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy
* History of allergies: allergic to the study drugs
* Metastasis: clinical symptoms of brain metastasis
* Other clinical trial: the subject received other clinical trial before this study
* Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus was positive
* Woman: pregnant or lactating women
* Compliance: poor compliance
* History of neoplasms: other neoplasms
Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients

This study is done to evaluate the effects of Mindfulness Based Cognitive Therapy (MBCT) for primary care patients that have mild to moderate symptoms of depression and anxiety. Half of the study participants will receive treatment as usual (TAU), and the other half will receive TAU plus MBCT. The investigators will be comparing changes in symptoms of depression and anxiety between the groups, and hypothesize that the TAU plus MBCT group will have significantly lower symptoms of depression and anxiety compared to TAU group post-intervention

Patients that show mild to moderate symptoms of depression and anxiety are common in the primary care setting. These patients are often treated with antidepressant or anxiolytic medication instead of cognitive therapy, which is the first choice of treatment according to clinical guidelines in Iceland. Although these patients are often referred to cognitive therapy, there are long waiting lists for group therapy and personal therapy is expensive. MBCT has been shown to have good effects on people with recurrent depression and on patients suffering from anxiety. Therefore, the investigators main objective is to assess whether MBCT is effective in the primary care setting for patients with mild symptoms of anxiety and depression and compare its effect to TAU.

Eligibility Criteria:
Inclusion Criteria:

* PHQ-9 and GAD-7 score 5-14 points
* Age18 - 67
* No current/recent psychotherapy of any kind other than his/hers physicians therapy( can be taking antidepressants but not in CBT)
* No regular meditation or yoga practice
* Not mentally retarded
* Speaks and understands Icelandic
* No current substance dependence
* Not diagnosed with schizophrenic symptoms or bipolar disease that that currently requires treatment
* Not participating in another mental health study

Exclusion Criteria:

1. Age: \<18 and \>67 years old.
2. Severe psychiatric symptoms requiring psychiatric care
3. Risk of suicide
4. Inability to participate in group sessions because of severe substance misuse;
5. Inability to speak and understand Icelandic
6. Pregnancy;
7. Current psychotherapy of any kind;
8. Participation in any other psychiatric intervention study;
9. Thyroid disease (if newly diagnosed by the doctor).
10. Score under 5 on both GAD7 and PHQ-9 and score over 14 on either GAD7 or PHQ-9.
11. One or more of the following ICD-10 psychiatric diagnoses:

F00-F09 Organic, including symptomatic, mental disorders F10-F19 Mental and behavioural disorders due to psychoactive substance use F20-F29 Schizophrenia, schizotypal and delusional disorders F70-F79 Mental retardation

-
The Assessment of Survival After In-hospital Cardiac Arrest for 2 Years in Tertiary Hospital

Define the frequency and survival pattern of cardiac arrests in relation to the hospital day of event and etiology of arrest.

Define the frequency and survival pattern of cardiac arrests in relation with event and etiology of arrest.

Investigators aims to evaluate the outcome of in-hospital cardiac arrests, focusing on the relationship between etiology and outcome.

Eligibility Criteria:
Inclusion Criteria:

* Cases where the cardiac arrest team is called

Exclusion Criteria:

* Lack of data records of patients
The Effect of Isokinetic Strengthening Training

Our participants will include 40 patients within one month of stroke, 43 patients who received total hip replacement or total knee replacement two to four weeks before. The participants will be randomly assigned to isokinetic, isotonic or isometric training groups. Outcome measures including isometric peak torque of hip/knee at 90 degree of flexion, peak torque of hip/knee at angular velocity of 60 degree/s and 120 degree/s, Short Form 36 (SF-36), the Timed Up and Go test, the Oxford Hip/knee Score, the plasma concentration of hsCRP, and the level of substance P in saliva will be collected at the beginning and 4 weeks after the training program. Statistical significant differences will be determined between the improvement of outcome measures of the isokinetic and the isotonic training groups.

Our participants will include 40 patients within one month of stroke, 43 patients who received total hip replacement or total knee replacement two to four weeks before. The participants will be randomly assigned to isokinetic, isotonic or isometric training groups. Outcome measures including isometric peak torque of hip/knee at 90 degree of flexion, peak torque of hip/knee at angular velocity of 60 degree/s and 120 degree/s, Short Form 36 (SF-36), the Timed Up and Go test, the Oxford Hip/knee Score, the plasma concentration of hsCRP, and the level of substance P in saliva will be collected at the beginning and 4 weeks after the training program. Statistical significant differences will be determined between the

Eligibility Criteria:
Inclusion Criteria:

* within one month of acute stroke
* receive total hip/knee replacement within two to four weeks before

Exclusion Criteria:

* cannot perform from sitting to standing
* Body Mass Index \> 30
* Lower limbs fracture history
* Diabetic polyneuropathy
* Cardiopulmonary diseases that impede exercise prescription
* Impaired cognitive function
* Infectious disease during the study period that may cause cytokine changes
The Effects of Rhus Coriaria L. on Body Weight

The aim of this study is to evaluate the effects of Rhus coriaria L. (Rhus) commonly known as "Somagh" on body weight.

Rhus coriaria L.(Rhus) is a well-known spice widely consumed in the world which has also been utilized extensively for medicinal purposes. The antioxidant components of this plant made it a favorable target for laboratory and animal studies in different conditions such as oxidative stress cytotoxicity, diabetes and hyperlipidemia. Rhus (Somagh) is found in temperate and tropical regions worldwide, often growing in areas of marginal agricultural capacity. Rhus is used as an herbal remedy in traditional medicine because of its assumed analgesic, antidiarrheic, antiseptic, anorexic and antihyperglycemic properties. The fruits of Rhus contain flavonols, phenolic acids, hydrolysable tannins, anthocyans and organic acids such as malice, citric and tartaric acids. Some studies have shown that polyphenols could have beneficial effects on cardiovascular disease and cancer and could be regarded as bioactive compounds with a high potential health-promoting capacity. Phenolic compounds inhibit lipid peroxidation, scavenge the superoxide anion and hydroxyl radical, and enhance the activities of detoxifying enzymes.

The aim of this study is to evaluate the effects of Rhus coriaria L. (Rhus) commonly known as Somagh on body weight.

Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) \>= 25 kg/m2

Exclusion Criteria:

* Diabetes mellitus
* Hypo. or hyperthyroidism
* Any systemic illnesses e.g. liver cirrhosis, acute or chronic renal failure, heart failure
* Use of drugs: Weight lowering agents, glucocorticoids, Oral contraceptive pills.
* Pregnancy
* History of allergic reaction to Somagh
Study Evaluating the Effect of Jublia on Dermatophytomas

This study will examine how Jublia affects dermatophytomas, which are difficult to treat with other therapeutic options.

Dermatophytomas are known to be resistant to even long courses of systemic antifungals, and have therefore been excluded from both topical and systemic clinical trials for onychomycosis, including those for Efinaconazole solution. Efinaconazole (Jublia) 10% solution is an FDA approved topical medication indicated for treatment of distal lateral subungual onychomycosis (DLSO), and the utility of this medication likely exceeds published results. Efinaconazole solution's novel ability to penetrate into the subungual space likely accounts for improved treatment results seen in DLSO treated with Jublia. We will investigate the utility of topical efinaconazole solution in the treatment of dermatophytomas.

Eligibility Criteria:
Inclusion Criteria:

* Has the informed consent been signed and patient's questions answered.
* Age \>= 18
* Patient willing and able to participate for the full duration of the study
* No onychomycosis
* Greater than 4 weeks from prior major surgery for any indication
* Willing to abstain from:

The application of other topical medications or cosmetic products to the toenail Professional pedicures for the duration of the study. - Females of childbearing potential must: Have been using adequate contraception (abstinence, intrauterine device (IUD), birth control pills or spermicidal gel with diaphragm or condom) since their last menses Agree to continue using adequate means of contraception (abstinence, IUD, birth control pills or spermicidal gel with diaphragm or condom) for the duration of study participation

Females are not considered to be of childbearing potential if they are at least 1 year postmenopausal or have had a tubal ligation, bilateral oophorectomy or hysterectomy.

Exclusion Criteria:

* Active onychomycosis of the toenails or fingernails
* Any of the following in the 4 weeks (or as indicated) prior to randomization:

Major surgery for any indication

- Any personal history of: Invasive cancer diagnosed or treated within the past 5 years. Participants who have been in remission for 5 years or more and have not required treatment in the past 5 years may be eligible if the principal investigator believes there is little to no risk of recurrence.

* Concurrent use of the following medications or treatments Other topical antifungals for any concomitant infection
* Females who are pregnant or lactating. Should a woman become pregnant or suspect she is pregnant while she is participating in this study she should notify the study physician immediately.
* Uncontrolled concurrent illness including ongoing or active infection, psychiatric illness/social situations that would limit compliance with study requirements or other underlying serious medical condition which, in the investigator's opinion, might preclude study participation.
Expiratory Rib Cage Compression in Mechanically Ventilated Patients

This is a randomized crossover study, designed to evaluate if the manual expiratory rib cage compression technique improves respiratory mechanics and is effective in secretion removal in mechanically ventilated patients.

Chest physiotherapy is an essential component of the multidisciplinary approach in critical care settings. In this context, a number of devices and manual techniques have been used to remove pulmonary secretions and re-expand collapsed areas. This study was designed to evaluate whether manual rib cage compression improves airway clearance and respiratory mechanics in mechanically ventilated patients. In a randomized crossover trial, 20 mechanically ventilated patients underwent thoracic manual compression and control intervention (normal ventilation) at the same day. The main outcomes were sputum production and the changes in respiratory mechanics.

Eligibility Criteria:
Inclusion Criteria:

* patients under mechanical ventilation
* diagnosis of pulmonary infection
* hypersecretive (defined as the interval between tracheal suctioning \< 2 hours)

Exclusion Criteria:

* haemodynamic instability (defined by heart rate \> 130 bpm and mean arterial pressure \< 60 mmHg)
* use of vasopressor drugs
* absence of respiratory drive
* acute bronchospasm
* acute respiratory distress syndrome
* atelectasis (identified by an independent radiologist that was not participating in the study)
* untreated pneumothorax
* lung haemorrhage.
Effects of Prevena Therapy on Obese and or Diabetic Patients With Surgical Groin Sites

The purpose of the study is to determine the effects of Prevena therapy on decreasing groin surgical site infections in patients who are obese and /or diabetic having vascular surgery.

Patients who are obese and/or diabetic may have poor surgical healing and infection rates higher. The PREVENA therapy will be used to evaluate possible reduction of infection rates in this patient population

Eligibility Criteria:
Inclusion Criteria:

* subjects over 18 years old
* obese (BMI \> 30) and or diabetic

Exclusion Criteria:

* current infected surgical field, hemodialysis, immunosuppressive therapy, allergy to adhesive, sensitivity to silver
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic HBV；
* Receiving anti-HB viral therapy;
* 10 IU/ml≤HBsAg≤3000 IU/ml.

Exclusion Criteria:

* Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;
* Liver cirrhosis;
* Hepatocellular carcinoma;
* Autoimmune liver disease;
* Clinical hepatic decompensation;
* Fibroscan\>12 kPa;
* a. hemoglobin\<110g/L（female）\<120 g/L（male），platelet\<ULN，white blood cell\<2.5×109/L；b. bilirubin\>1.5 ×ULN，ALT\>2 × ULN，serum albumin\<35 g/L；c. INR\>1.5；d. serum creatinine \>1.5×ULN.
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who was included in study ONO-5920-02 and completed the medication for two years
2. Other inclusion criteria as specified in the study protocol

Exclusion Criteria:

1. Patients judged to be unsuitable by safety evaluation as clinical trial subjects by the investigator
2. Patients having secondary osteoporosis or another condition that presents low bone mass
3. Other exclusion criteria as specified in the study protocol
Health & Digital Literacy and Complementary Medicine Attitudes in Rehabilitation Patients

This observational study aims to evaluate the relationship between health and digital health literacy and attitudes toward complementary and alternative medicine (CAM) in patients visiting a physical medicine and rehabilitation outpatient clinic. Low health literacy may lead patients to try potentially unsafe herbal products influenced by commercial or social media sources. This study highlights the importance of understanding patients' attitudes toward such methods and aims to contribute to the development of educational efforts to improve health literacy. Increasing patients' awareness can support better decision-making, enhance rehabilitation outcomes, and promote the use of evidence-based practices in physical medicine clinics..

This non-interventional clinical study will be conducted at the Physical Medicine and Rehabilitation outpatient clinic of Karabük Training and Research Hospital. The study population will consist of at least 200 volunteer patients aged 18 to 65 years. The aim is to determine the participants' level of health literacy, their perspectives on CAM, and the relationship between these two variables.

The inclusion criteria include being aged 18-65, being literate, and volunteering to participate. Patients who are unwilling or unable to cooperate will be excluded. Participants will complete four tools: a sociodemographic form, the Health Literacy Index (25 items), the Digital Health Literacy Instrument (18 items, 6 subscales), and the Complementary and Alternative Medicine Attitude Scale (27 items, 3 subscales).

Data analysis will be performed using SPSS software. Tests such as Kolmogorov-Smirnov, Pearson and Spearman correlation will be applied depending on the distribution and type of data. The study results will contribute to understanding the educational needs of patients regarding CAM and help promote evidence-based decision-making in clinical rehabilitation settings.

Eligibility Criteria:
Inclusion Criteria:

* being aged 18-65
* being literate
* Volunteering to participate

Exclusion Criteria:

* Patients who are unwilling or unable to cooperate